Importantly, FNDC5 expression is decreased in paclitaxel-resistant non-small-cell lung cancer, and exogenous irisin can increase the sensitivity of lung cancer to paclitaxel, thus contributing to treatment. This evidence concerns the gene FNDC5 and non-small cell lung carcinoma.